CN107375346A - 提高人类精子浓度和运动性的组合物及其制备方法 - Google Patents
提高人类精子浓度和运动性的组合物及其制备方法 Download PDFInfo
- Publication number
- CN107375346A CN107375346A CN201710611843.9A CN201710611843A CN107375346A CN 107375346 A CN107375346 A CN 107375346A CN 201710611843 A CN201710611843 A CN 201710611843A CN 107375346 A CN107375346 A CN 107375346A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- motility
- sperm
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004899 motility Effects 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 26
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 26
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 239000011669 selenium Substances 0.000 claims abstract description 17
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 17
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 15
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 13
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 13
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000001413 amino acids Chemical class 0.000 claims abstract description 13
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 13
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 13
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 13
- 239000001168 astaxanthin Substances 0.000 claims abstract description 13
- 229960000304 folic acid Drugs 0.000 claims abstract description 13
- 235000019152 folic acid Nutrition 0.000 claims abstract description 13
- 239000011724 folic acid Substances 0.000 claims abstract description 13
- 229960003080 taurine Drugs 0.000 claims abstract description 13
- 239000011701 zinc Substances 0.000 claims abstract description 13
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 13
- 229930091371 Fructose Natural products 0.000 claims abstract description 12
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 12
- 239000005715 Fructose Substances 0.000 claims abstract description 12
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims abstract description 12
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 12
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 12
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 12
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 11
- 229940046009 vitamin E Drugs 0.000 claims abstract description 11
- 239000011709 vitamin E Substances 0.000 claims abstract description 11
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000001014 amino acid Nutrition 0.000 claims description 12
- SQVRNKJHWKZAKO-LUWBGTNYSA-N N-acetylneuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)CC(O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-LUWBGTNYSA-N 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 4
- 229930064664 L-arginine Natural products 0.000 claims description 4
- 235000014852 L-arginine Nutrition 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 239000004376 Sucralose Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- -1 D-mannital Substances 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 125000003748 selenium group Chemical group *[Se]* 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 230000019100 sperm motility Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000000750 progressive effect Effects 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 230000033001 locomotion Effects 0.000 abstract description 3
- 206010067482 No adverse event Diseases 0.000 abstract description 2
- 230000003078 antioxidant effect Effects 0.000 abstract description 2
- 230000002045 lasting effect Effects 0.000 abstract description 2
- 210000004995 male reproductive system Anatomy 0.000 abstract description 2
- 230000001590 oxidative effect Effects 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 229960002737 fructose Drugs 0.000 abstract 1
- 229940091258 selenium supplement Drugs 0.000 abstract 1
- 206010003883 azoospermia Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 5
- 206010003495 Aspermia Diseases 0.000 description 5
- 229960004203 carnitine Drugs 0.000 description 5
- 208000008634 oligospermia Diseases 0.000 description 5
- 230000036616 oligospermia Effects 0.000 description 5
- 231100000528 oligospermia Toxicity 0.000 description 5
- 206010021929 Infertility male Diseases 0.000 description 3
- 208000007466 Male Infertility Diseases 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004822 varicocele Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种提高人类精子浓度和运动性的组合物，采用左旋肉碱、乙酰左旋肉碱、氨基酸、牛磺酸、果糖、硒源、锌源、叶酸、维生素B12、维生素E、虾青素、N‑乙酰神经氨酸作为原料并适当配比，各种组分间协同作用，能有效调节男性生殖系统中的氧化与抗氧化动态平衡，促进精子生成，使精子免于聚积导致运动受阻，提高精子的成活率，增强精子的活动力，最终有效提高人类精子浓度和运动性；本发明所述药物能够适应复杂病情的治疗要求，无不良反应，疗效显著持久，安全可靠，服用方便，是治疗各种原因引起的精子前向运动能力差、精子浓度低、精子活率低下的有效药物。数据显示，本发明所述的提高人类精子浓度和运动性的组合物，治疗有效率高达96％。
Description
技术领域
本发明属于药物技术领域，具体涉及一种提高人类精子浓度和运动性的组合物及其制备方法。
背景技术
随着环境污染的日益加重，工作生活压力的不断增大，加之不良的生活习惯，近年来我国不育症的发病率呈不断上升的趋势，给患者本人和家属带来了沉重的精神和经济负担，成为影响家庭和睦的重要因素之一。不育不仅是家庭问题，也逐渐成为一个全球性的公共社会问题，成为许多国家生殖健康服务的重要内容之一。在不育病例中，男性不育约占到30-40％男性不育的原因很多，例如睾丸发育异常、精索静脉曲张、性功能障碍以及各种内科疾病并发的不育等，但是高达60-75％的患者找不到原因，他们一般表现为精子前向运动能力差、精子浓度低、精子活率低下等精子质量异常症状。
目前，对于男性不育症的治疗，西医的诸多疗法中往往只能针对单一病变组织施治，而无法达到全面治疗、全面调理之效；并且对于精子前向运动能力差、精子浓度低、精子活率低下，主要是采用各种激素治疗，虽有一定的疗效，但都存在不同程度的副作用；中医对本病的认识基本都是肾精不足，治疗有偏于温补益肾和滋阴补肾两大类；中成药也有很多，但长期服用后，治疗效果并不明显。
发明内容
为了解决现有技术存在的上述问题，本发明提供了一种配方科学、疗效显著、安全可靠能有效促进精子生成、提高精子成活率、增强精子活动力的提高人类精子浓度和运动性的组合物及其制备方法。
本发明所采用的技术方案为：
一种提高人类精子浓度和运动性的组合物，原料组分包括：左旋肉碱4-10重量份、乙酰左旋肉碱2-8重量份、氨基酸2-5重量份、牛磺酸0.1-0.2重量份、果糖5-15重量份、硒源0.01-0.1重量份、锌源0.01-0.1重量份、叶酸0.001-0.01重量份、维生素B12 0.1-1重量份、维生素E 0.1-1重量份、虾青素0.01-0.1重量份、N-乙酰神经氨酸0.001-0.01重量份。
进一步优选所述的提高人类精子浓度和运动性的组合物的原料组分包括：左旋肉碱6-8重量份、乙酰左旋肉碱4-6重量份、氨基酸3-4重量份、牛磺酸0.12-0.18重量份、果糖8-12重量份、硒源0.04-0.08重量份、锌源0.04-0.08重量份、叶酸0.004-0.008重量份、维生素B12 0.4-0.6重量份、维生素E 0.4-0.6重量份、虾青素0.04-0.06重量份、N-乙酰神经氨酸0.004-0.006重量份。
进一步优选所述的提高人类精子浓度和运动性的组合物的原料组分包括：左旋肉碱7重量份、乙酰左旋肉碱5重量份、氨基酸3.5重量份、牛磺酸0.15重量份、果糖10重量份、硒源0.05重量份、锌源0.05重量份、叶酸0.005重量份、维生素B12 0.5重量份、维生素E 0.5重量份、虾青素0.05重量份、N-乙酰神经氨酸0.005重量份。
所述氨基酸为L-精氨酸。
所述硒源为硒酵母。
所述锌源为甘氨酸锌。
所述果糖为低聚果糖。
所述原料组分还包括1-5重量份的调味剂。
所述调味剂为蜂蜜冻干粉、木糖醇、D-甘露糖醇、三氯蔗糖中的一种或几种的混合物。
一种制备所述的提高人类精子浓度和运动性的组合物的方法，包括如下步骤：
分别称取各原料并进行充分混合，即得所述提高人类精子浓度和运动性的组合物。
本发明的有益效果为：
本发明所述的提高人类精子浓度和运动性的组合物，采用左旋肉碱、乙酰左旋肉碱、氨基酸、牛磺酸、果糖、硒源、锌源、叶酸、维生素B12、维生素E、虾青素、N-乙酰神经氨酸作为原料并进行适合配比，利用各种组分相互间的协同作用，能有效调节男性生殖系统中的氧化与抗氧化动态平衡，促进精子生成，使精子免于聚积导致运动受阻，提高精子的成活率，增强精子的活动力，最终有效提高人类精子浓度和运动性；本发明所述药物能够适应复杂病情的治疗要求，无不良反应，疗效显著持久，安全可靠，服用方便，是治疗各种原因引起的精子前向运动能力差、精子浓度低、精子活率低下的有效药物。数据显示，本发明所述的提高人类精子浓度和运动性的组合物，治疗有效率高达97％。
具体实施方式
下面实施例中以1重量份代表1g。
实施例1
本实施例提供一种提高人类精子浓度和运动性的组合物，其原料组分包括：左旋肉碱4重量份、乙酰左旋肉碱8重量份、L-精氨酸2重量份、牛磺酸0.2重量份、低聚果糖5重量份、硒酵母0.1重量份、甘氨酸锌0.01重量份、叶酸0.01重量份、维生素B12 0.1重量份、维生素E 1重量份、虾青素0.01重量份、N-乙酰神经氨酸0.01重量份、蜂蜜冻干粉1重量份。
分别称取各原料并进行充分混合，即得所述提高人类精子浓度和运动性的组合物。
实施例2
本实施例提供一种提高人类精子浓度和运动性的组合物，其原料组分包括：左旋肉碱10重量份、乙酰左旋肉碱2重量份、L-精氨酸5重量份、牛磺酸0.1重量份、低聚果糖15重量份、硒酵母0.01重量份、甘氨酸锌0.1重量份、叶酸0.001重量份、维生素B12 1重量份、维生素E 0.1重量份、虾青素0.1重量份、N-乙酰神经氨酸0.001重量份、木糖醇5重量份。
分别称取各原料并进行充分混合，即得所述提高人类精子浓度和运动性的组合物。
实施例3
本实施例提供一种提高人类精子浓度和运动性的组合物，其原料组分包括：左旋肉碱6重量份、乙酰左旋肉碱6重量份、氨基酸3重量份、牛磺酸0.18重量份、果糖8重量份、硒源0.08重量份、锌源0.04重量份、叶酸0.008重量份、维生素B12 0.4重量份、维生素E0.6重量份、虾青素0.04重量份、N-乙酰神经氨酸0.006重量份、D-甘露糖醇3重量份。
分别称取各原料并进行充分混合，即得所述提高人类精子浓度和运动性的组合物。
实施例4
本实施例提供一种提高人类精子浓度和运动性的组合物，其原料组分包括：左旋肉碱8重量份、乙酰左旋肉碱4重量份、氨基酸4重量份、牛磺酸0.12重量份、果糖12重量份、硒源0.04重量份、锌源0.08重量份、叶酸0.004重量份、维生素B12 0.6重量份、维生素E 0.4重量份、虾青素0.06重量份、N-乙酰神经氨酸0.004重量份、三氯蔗糖4重量份。
分别称取各原料并进行充分混合，即得所述提高人类精子浓度和运动性的组合物。
实施例5
本实施例提供一种提高人类精子浓度和运动性的组合物，其原料组分包括：左旋肉碱7重量份、乙酰左旋肉碱5重量份、氨基酸3.5重量份、牛磺酸0.15重量份、果糖10重量份、硒源0.05重量份、锌源0.05重量份、叶酸0.005重量份、维生素B12 0.5重量份、维生素E0.5重量份、虾青素0.05重量份、N-乙酰神经氨酸0.005重量份、木糖醇2.5重量份。
分别称取各原料并进行充分混合，即得所述提高人类精子浓度和运动性的组合物。
实验例
本发明人通过对就诊的300例少精弱精症患者进行临床验证，年龄23-40岁，病程2-9年，其中少精症100，弱精症100例，少精弱精症100例。
(1)诊断标准：夫妻同居一年以上，性生活正常，未采取任何避孕措施而不育，经检查排除女方因素者。精液检查异常指：(a)精子密度<60×109/L；(b)精子活力a+b级<30％或者a级<10％；(c)精子活率<60％，以上三项具备一项即可确诊。
(2)治疗方法：口服，用水冲服，每次15克，每日2次。
治疗期间患者停止服用其他药物，禁烟酒、勿劳累、忌高温作业及热水泡浴，避免工业污染、放射线及电磁波，穿棉质宽松衣裤，注意营养平衡，并嘱患者配偶倍加关心、鼓励，以减轻患者压力、增强信心。随访患者妻子受孕情况。
(3)疗效评定标准：
疗效标准根据世界卫生组织《不育夫妇标准检查与诊断手册》，并参照《中药新药临床研究指导原则》中有关疗效标准进行评定。
临床治愈：少精症治疗后精子密度≧20×109/L，弱精症精子活动力a级≧25％或a+b级≧50％，或治疗后女方怀孕。
显效：少精症治疗后精子密度提升≧50％，弱精症精子活动力a+b级提升≧25％或a级提升≧12.5％，但未达到正常指标。
有效：少精症治疗后精子密度提升≧15％，弱精症精子活动力a+b级或a级提升≧5％。
无效：治疗后精子密度提升<15％及精子活力提升<5％或无变化。
(4)治疗前后各组疗效见表1，治疗前后各组的精液参数比较见表2。
表1-治疗前后各组疗效
| 组别 | 治愈 | 显效 | 有效 | 无效 | 总有效率 |
| 少精症组 | 56 | 29 | 11 | 4 | 96％ |
| 弱精症组 | 65 | 20 | 12 | 3 | 96％ |
| 少精弱精症组 | 33 | 28 | 30 | 9 | 90％ |
表2-治疗前后各组的精液参数比较
本发明不局限于上述最佳实施方式，任何人在本发明的启示下都可得出其他各种形式的产品，但不论在其形状或结构上作任何变化，凡是具有与本申请相同或相近似的技术方案，均落在本发明的保护范围之内。
Claims (10)
1.一种提高人类精子浓度和运动性的组合物，其特征在于，原料组分包括：左旋肉碱4-10重量份、乙酰左旋肉碱2-8重量份、氨基酸2-5重量份、牛磺酸0.1-0.2重量份、果糖5-15重量份、硒源0.01-0.1重量份、锌源0.01-0.1重量份、叶酸0.001-0.01重量份、维生素B120.1-1重量份、维生素E 0.1-1重量份、虾青素0.01-0.1重量份、N-乙酰神经氨酸0.001-0.01重量份。
2.根据权利要求1所述的提高人类精子浓度和运动性的组合物，其特征在于，原料组分包括：左旋肉碱6-8重量份、乙酰左旋肉碱4-6重量份、氨基酸3-4重量份、牛磺酸0.12-0.18重量份、果糖8-12重量份、硒源0.04-0.08重量份、锌源0.04-0.08重量份、叶酸0.004-0.008重量份、维生素B12 0.4-0.6重量份、维生素E 0.4-0.6重量份、虾青素0.04-0.06重量份、N-乙酰神经氨酸0.004-0.006重量份。
3.根据权利要求1所述的提高人类精子浓度和运动性的组合物，其特征在于，原料组分包括：左旋肉碱7重量份、乙酰左旋肉碱5重量份、氨基酸3.5重量份、牛磺酸0.15重量份、果糖10重量份、硒源0.05重量份、锌源0.05重量份、叶酸0.005重量份、维生素B12 0.5重量份、维生素E 0.5重量份、虾青素0.05重量份、N-乙酰神经氨酸0.005重量份。
4.根据权利要求1-3任一项所述的提高人类精子浓度和运动性的组合物，其特征在于，所述氨基酸为L-精氨酸。
5.根据权利要求1-3任一项所述的提高人类精子浓度和运动性的组合物，其特征在于，所述硒源为硒酵母。
6.根据权利要求1-3任一项所述的提高人类精子浓度和运动性的组合物，其特征在于，所述锌源为甘氨酸锌。
7.根据权利要求1-3任一项所述的提高人类精子浓度和运动性的组合物，其特征在于，所述果糖为低聚果糖。
8.根据权利要求1-3任一项所述的提高人类精子浓度和运动性的组合物，其特征在于，所述原料组分还包括1-5重量份的调味剂。
9.根据权利要求1-3任一项所述的提高人类精子浓度和运动性的组合物，其特征在于，所述调味剂为蜂蜜冻干粉、木糖醇、D-甘露糖醇、三氯蔗糖中的一种或几种的混合物。
10.一种制备权利要求1-9任一项所述的提高人类精子浓度和运动性的组合物的方法，其特征在于，包括如下步骤：
分别称取各原料并进行充分混合，即得所述提高人类精子浓度和运动性的组合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710611843.9A CN107375346A (zh) | 2017-07-25 | 2017-07-25 | 提高人类精子浓度和运动性的组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710611843.9A CN107375346A (zh) | 2017-07-25 | 2017-07-25 | 提高人类精子浓度和运动性的组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107375346A true CN107375346A (zh) | 2017-11-24 |
Family
ID=60337192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710611843.9A Pending CN107375346A (zh) | 2017-07-25 | 2017-07-25 | 提高人类精子浓度和运动性的组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107375346A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110613124A (zh) * | 2019-09-18 | 2019-12-27 | 孙启城 | 一种含有左旋肉碱和虾青素的保健食品 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1284871A (zh) * | 1997-12-01 | 2001-02-21 | 希格马托保健科学股份公司 | 增加人类精子的浓度和运动性的组合物及方法 |
| CN102846673A (zh) * | 2012-03-21 | 2013-01-02 | 陈浩 | 改善人类精子活动力与质量的组合物 |
| CN105596885A (zh) * | 2016-01-14 | 2016-05-25 | 梁晓会 | 治疗男性少精弱精、提高精子质量的药物及其制备方法 |
| CN106668507A (zh) * | 2016-12-29 | 2017-05-17 | 昭远制药(上海)有限公司 | 一种用于治疗男性不孕不育的药物及其制备方法 |
-
2017
- 2017-07-25 CN CN201710611843.9A patent/CN107375346A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1284871A (zh) * | 1997-12-01 | 2001-02-21 | 希格马托保健科学股份公司 | 增加人类精子的浓度和运动性的组合物及方法 |
| CN102846673A (zh) * | 2012-03-21 | 2013-01-02 | 陈浩 | 改善人类精子活动力与质量的组合物 |
| CN105596885A (zh) * | 2016-01-14 | 2016-05-25 | 梁晓会 | 治疗男性少精弱精、提高精子质量的药物及其制备方法 |
| CN106668507A (zh) * | 2016-12-29 | 2017-05-17 | 昭远制药(上海)有限公司 | 一种用于治疗男性不孕不育的药物及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 冯颖等: "唾液酸在精子成熟、获能及精卵结合中作用研究进展", 《中华男科学杂志》 * |
| 黎娜等: "唾液酸对精子的作用", 《中国细胞生物学学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110613124A (zh) * | 2019-09-18 | 2019-12-27 | 孙启城 | 一种含有左旋肉碱和虾青素的保健食品 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083468B (zh) | 一种治疗男性少精弱精、提高精子质量的药物 | |
| Ormsbee et al. | Osteosarcopenic obesity: the role of bone, muscle, and fat on health | |
| Opazo et al. | The impact of the micronutrient iodine in health and diseases | |
| US20030119913A1 (en) | Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof | |
| Correia et al. | Changing management guidelines in thyrotoxic hypokalemic periodic paralysis | |
| US9943503B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| Emine et al. | The effect of salt-water bath in the management of treatment-related peripheral neuropathy in cancer patients receiving taxane and platinum-based treatment | |
| CN107375346A (zh) | 提高人类精子浓度和运动性的组合物及其制备方法 | |
| McKenzie et al. | Short-term exposure to a clinical dose of metformin increases skeletal muscle mitochondrial H2O2 emission and production in healthy, older adults: A randomized controlled trial | |
| US20230089950A1 (en) | Lithium ion composition and application thereof | |
| US10149831B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| Hamed et al. | Comparison between oral zinc and agar with phototherapy in the treatment of neonatal jaundice: A prospective clinical trial study | |
| ZA200307594B (en) | Method for increasing serotonin levels in a person by administration of a composition incorporating hydroxycitric acid and related compositions thereof | |
| Nandy et al. | A prescription survey in diabetes assessing metformin use in a tertiary care hospital in Eastern India | |
| US20040157929A1 (en) | Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof | |
| CN111588740A (zh) | 一种提高免疫力的茶黄素组合物及其制备方法 | |
| Anisha | Ayurvedic management of Premenstrual Syndrome-A Case Study | |
| Sane et al. | Impact of low-carbohydrate diet (LCD) and obesity management program on obese patients | |
| CN109966498A (zh) | 一种抗抑郁症的药物组合物及其用途 | |
| Khan et al. | Clinical efficacy of Unani formulation in type II diabetes-A randomized, single blind standard control clinical study | |
| US10166265B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| CN107412240A (zh) | 一种组合物及其应用 | |
| Chan | Synergistic Welfare of Synbiotic Nutraceuticals on Reproductive Health | |
| Tanwar et al. | Ayurvedic approach to manage Polycystic Ovarian Syndrome with Yoga Basti-A Case Study | |
| Dananjaya et al. | THYROTOXIC PERIODIC PARALYSIS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171124 |